Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Other Liabilities
Gensight Biologics SA
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Gensight Biologics SA
PAR:SIGHT
|
Other Liabilities
€6.9m
|
CAGR 3-Years
27%
|
CAGR 5-Years
138%
|
CAGR 10-Years
N/A
|
||
Valneva SE
PAR:VLA
|
Other Liabilities
€7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Innate Pharma SA
PAR:IPH
|
Other Liabilities
€6.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
15%
|
||
G
|
Genfit SA
PAR:GNFT
|
Other Liabilities
€1m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-13%
|
|
Inventiva SA
PAR:IVA
|
Other Liabilities
€23.5m
|
CAGR 3-Years
85%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
||
Eurobio Scientific SA
PAR:ALERS
|
Other Liabilities
€1.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
0%
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Other Liabilities?
Other Liabilities
6.9m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Other Liabilities amounts to 6.9m EUR.
What is Gensight Biologics SA's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
138%
Over the last year, the Other Liabilities growth was -4%. The average annual Other Liabilities growth rates for Gensight Biologics SA have been 27% over the past three years , 138% over the past five years .